The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 65 of the 154 sources its claims cite were checked for support.
Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review
Open accessPublished version of a preprint
Abstract
Background: According to the World Health Organization, the worldwide prevalence of diabetes mellitus (DM) is increasing dramatically and DM comprises a large part of the global burden of disease. At the same time, the ongoing digitalization that is occurring in society today offers novel possibilities to deal with this challenge, such as the creation of mobile health (mHealth) apps. However, while a great variety of DM-specific mHealth apps exist, the evidence in terms of their clinical effectiveness is still limited. Objective: The objective of this review was to evaluate the clinical effectiveness of mHealth apps in DM management by analyzing health-related outcomes in patients diagnosed with type 1 DM (T1DM), type 2 DM (T2DM), and gestational DM. Methods: A scoping review was performed. A systematic literature search was conducted in MEDLINE (PubMed), Cochrane Library, EMBASE, CINAHL, and Web of Science Core Collection databases for studies published between January 2008 and October 2020. The studies were categorized by outcomes and type of DM. In addition, we carried out a meta-analysis to determine the impact of DM-specific mHealth apps on the management of glycated hemoglobin (HbA1c). Results: In total, 27 studies comprising 2887 patients were included. We analyzed 19 randomized controlled trials, 1 randomized crossover trial, 1 exploratory study, 1 observational study, and 5 pre-post design studies. Overall, there was a clear improvement in HbA1c values in patients diagnosed with T1DM and T2DM. In addition, positive tendencies toward improved self-care and self-efficacy as a result of mHealth app use were found. The meta-analysis revealed an effect size, compared with usual care, of a mean difference of –0.54% (95% CI –0.8 to –0.28) for T2DM and –0.63% (95% CI –0.93 to –0.32) for T1DM. Conclusions: DM-specific mHealth apps improved the glycemic control by significantly reducing HbA1c values in patients with T1DM and T2DM patients. In general, mHealth apps effectively enhanced DM management. However, further research in terms of clinical effectiveness needs to be done in greater detail.
Overview
CoChat Summary
TL;DR
This scoping review of 27 studies comprising 2887 patients found that diabetes-specific mHealth apps improved glycemic control, with meta-analytic HbA1c reductions versus usual care for type 2 and type 1 diabetes mellitus. Evidence for other outcomes was limited or inconclusive.
Key findings
- Across 27 studies, HbA1c meta-analysis showed a mean difference of –0.54% (95% CI –0.8 to –0.28) for T2DM (8 studies) and –0.63% (95% CI –0.93 to –0.32) for T1DM (2 studies), compared with usual care.
- In T1DM, 3 of 7 studies found significant within-group HbA1c improvements (mean differences: –1.1%, P<.001; –0.3%, P<.001; –0.3%, P=.04), yielding an average HbA1c of 7.73%; 2 studies found significant between-group differences favoring app intervention (P<.001; –0.67%, P<.001).
- In T2DM, 11 studies reported a within-group HbA1c decrease (mean difference –0.42%), but only 1 reported a significant change of –1.1% (P<.001); 7 of 11 studies with control groups reported significant between-group differences (mean difference –0.78%, –1.51 to –0.35). Fasting blood glucose improved significantly in 2 studies (–28.23 mg/dL, P<.001; –9.6 mg/dL, P=.019), while none of 7 studies reporting blood pressure found significant differences.
- In GDM, data were limited: 1 study found a significant between-group HbA1c difference favoring the app (–1.3% vs –0.6%, P<.001), while another found no significant difference; positive tendencies were reported for self-care and self-efficacy overall.
Methods
- Scoping review with a systematic literature search in MEDLINE (PubMed), Cochrane Library, EMBASE, CINAHL, and Web of Science Core Collection for studies published January 2008 to October 2020, restricted to German and English; screening and selection were done by two independent reviewers.
- Included primary research studies (randomized controlled trials, exploratory studies, observational studies, and pre-post design studies) reporting clinical effectiveness of DM-specific mHealth apps in T1DM, T2DM, and GDM, specifying app features and health effects; excluded posters, comments, study protocols, duplicates, and studies focused on DM diagnosis or prevention.
- Data were extracted on author, year, study design, intervention and control groups, baseline and follow-up HbA1c, DM type, sample size, and main findings; studies were synthesized by outcome, and a meta-analysis pooled studies with mHealth-app-only intervention groups versus usual care that reported HbA1c changes as percentages.
Limitations
- The paper states a major limitation is the small sample size, especially for GDM: only 4 GDM studies were included, they reported predominantly different outcomes, and no effects of mHealth app use could be determined for GDM.
- The paper states that the quality of included studies was not assessed, so it cannot judge whether an effect was based on poor study quality.
- Evident from the text: heterogeneity in DM type, study design, participant numbers, app features, and co-interventions (eg, web portals, HCP feedback, Bluetooth-enabled devices) prevented distinguishing a relationship between specific app features and health outcomes; data were also limited for hypo- and hyperglycemia, further glycemic control parameters, self-care, and self-efficacy.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
38 Valid · 1 Not valid · 39 Not checked · 44 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“while 3 studies did not find a significant difference between groups [52,59,60] and 1 study did not report on differences between groups [61].”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
What the sources say
- Disputedcites [61] sourceExperimental — accuracy not yet measured
Our copy of Kim et al. (2014) explicitly reports between-group results: the RESULTS section 'Effect on blood glucose level' states the control group showed no change from baseline 'thus showing no intergroup difference after 3 months' and that lipid levels showed 'no significant intergroup differences (Table 2)'. The 'Subgroup analysis by compliance' section again contrasts the less satisfied group with the control group, and the Statistical analysis describes a Kruskal-Wallis test across high-compliance, low-compliance and control groups. So the study is a T2DM trial that did report on differences between groups (finding none significant overall), contrary to what the citing sentence attributes to reference [61]. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the available evidence on the effectiveness of DM-specific mHealth apps is limited [39].”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Introduction
What the sources say
- Supportedcites [39] source
The Abstract (p. 5) states verbatim that 'The available evidence on the safety and effectiveness of mobile health apps, especially for diabetes, remains limited,' and the scope of the consensus report is standalone diabetes apps. The 'Issues faced by the diabetes community' section (pp. 16-17) reinforces this: Zhao et al.'s review yielded only 10 diabetes-relevant app studies, the 2018 AHRQ report found only 11 RCTs with clinically significant HbA1c improvements in five and none in quality of life, BP, weight or BMI, with no study rated high quality, and the section concludes such studies 'are extremely limited in both quantity and quality.' (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite the huge improvements in diabetes technologies, such as glucose monitoring systems and insulin pumps, many people with diabetes do not meet glycemic control targets [23] and would benefit from greater flexibility and more individualized diabetes therapy.”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Introduction
What the sources say
- Supportedcites [23] source
The Results (Fig. 1 discussion) state that in the most recent NHANES wave (2011–2014) only about half (50.9%, 95% CI 47.2–54.7%) of people with diabetes had HbA1c <7.0% and under two-thirds (63.8%) achieved individualized targets, i.e. a large share did not meet glycemic targets; the Abstract Results add that 15.5% had HbA1c >9.0%, and the Abstract Conclusions state the proportion achieving glycemic control targets has not improved. The only qualifier the source carries that the citing sentence drops is that this is a US nationally representative adult population, which does not alter the paraphrased point. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“while 3 studies did not find a significant difference between groups [52,59,60] and 1 study did not report on differences between groups [61].”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
What the sources say
- Supportedcites [52] source
The Results (Primary outcomes) state that the between-group differences in HbA1c and the other primary outcome were not statistically significant. The Results (Secondary outcomes) likewise report no statistically significant differences between the intervention and control groups. This supports citing the TRIGGER study as one of the three studies; it does not establish the findings of the other two. (LLM, conf=0.94)
- Supportedcites [59] source
The Results (Table 3) show no significant between-group difference in HbA1c change for either intervention group versus control (adjusted P=.42 and P=.97). This supports the cited paper's inclusion among studies with no significant between-group difference; it does not independently establish the findings of the other two cited studies. (LLM, conf=0.93)
- Supportedcites [60] source
The Results section (‘Changes in HbA1c from baseline to 12 Months’; page not provided) reports that the treatment effect was not statistically significant (P = 0.771) and that treatment-by-time interactions were also not significant. This supports citing this trial as one of the studies that found no significant between-group difference in glycemic control; it does not need to establish the results of the other two cited studies. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, Kim et al [61] found a significant decrease of 0.4% (P<.001) in HbA1c in their subgroup analysis for participants with a high satisfaction level and no significant decrease in participants with a low satisfaction level.”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
What the sources say
- Supportedcites [61] source
The subgroup analysis by compliance/satisfaction (RESULTS, p. ~4) reports HbA1c falling from 7.7%±0.8% to 7.3%±0.6% (P<0.001) in the more satisfied group (n=27), a 0.4% decrease, while in the less satisfied group (n=8) HbA1c did not fall significantly (7.7%±0.4% to 8.1%±0.5%, P=0.062), with P for interaction=0.0004. The Abstract and Discussion repeat both figures, and METHODS confirms the population is type 2 diabetes outpatients, so both parts of the citing sentence match the source. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
68 more claims · 27 with their cited sources checked
Create a free account to see all 122 claims and to verify the 89 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 23
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that digital technology has the potential to support people living with T2DM in their efforts toward achieving their glycemic goals [11,12].”
From Digital Interventions for Self-Management of Type 2 Diabetes Mellitus: Systematic Literature Review and Meta-Analysis (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Existing reviews often focus on specific types of telemedicine tools [19-21], settings [22], or providers [23], which limit generalizability across broader diabetes care contexts.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
“but only 1 study reported a significant change of –1.1% (P<.001) [56].”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > Effects on HbA1c
“(A) –0.40 (–0.67 to –0.14); (B) 0.036 (–0.23 to 0.30)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
“Three studies [52,55,59] observed the body weights of 215 patients in intervention groups and 156 patients in control groups.”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
“One study reported a significant difference between the groups (–2.1 kg in the intervention group versus 0.4 kg in the control group; P=.021) [51].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Discussion > Principal Results and Comparison With Prior Work
“While no significant improvements in blood pressure or cholesterol were found in patients with T2DM”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > T2DM Studies
“With regard to LDL cholesterol, 1 study reported a significant change within the intervention group (–20.42 mg/dL; P=.007) and between the intervention and control groups (P=.01) [56].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > Overview
“Furthermore, we excluded 8 unsuitable studies based on their full texts. After the additional manual research, which identified 2 papers, there was a total of 27 suitable studies to include in this scoping review.”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > Overview
“After removing the duplicates, there were 654 citations. Based on the titles and abstracts, we excluded 619 unsuitable papers.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“(A) 8.74 (1.34); (B) 8.18 (1.02) | (A) 7.64 (1.29); (B) 7.91 (0.88) | (A) –1.1, P<.001; (B) 0.27, P=.208”
§ Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review > Results > Effects on HbA1c
Reported 0.27 · recomputed -0.27
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · cited 1×
“In October 2020, we conducted a systematic literature search in MEDLINE via PubMed, Cochrane Library, EMBASE, CINAHL, and Web of Science Core Collection in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) strategy [41].”
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends
Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Al Kaabi, J. (2019) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.191028.001 · Cited by 3,130 · cited 2×
“Diabetes mellitus (DM) affects millions of people worldwide and its prevalence is rising [19,20].”
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850 · cited 1×
“Affecting approximately 462 million people globally, T2DM makes up a significant part of the global burden [19], but the prevalence of T1DM, gestational DM (GDM), and other forms of DM are rising drastically as well [20-22].”
Quinn, C. C., Shardell, M. D., Terrin, M. L., Barr, E. A., Ballew, S. H., & Gruber-Baldini, A. L. (2011) · Diabetes Care · doi:10.2337/dc11-0366 · Cited by 650 · cited 2×
“High-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol were both included in 7 studies [52,53,55-58 , 61].”
Osborne, R. H., Elsworth, G. R., & Whitfield, K. (2007) · Patient Education and Counseling · doi:10.1016/j.pec.2006.12.002 · Cited by 556 · cited 1×
“Chomutare et al [50] (7 patients) reported improvements in scores on the DES–SF and Health Education Impact Questionnaire (heiQ [70]), but they did not report on significance.”
A qualitative study of user perceptions of mobile health apps
Peng, W., Kanthawala, S., Yuan, S., & Hussain, S. A. (2016) · BMC Public Health · doi:10.1186/s12889-016-3808-0 · Cited by 465 · cited 1×
“Because the mHealth app market is very heterogeneous and growing so rapidly, there is currently no general mandated definition of mHealth app [10,11].”
Taylor, S. J., Pinnock, H., Epiphaniou, E., Pearce, G., Parke, H. L., Schwappach, A., Purushotham, N., Jacob, S., Griffiths, C. J., Greenhalgh, T., et al. (2014) · Health Services and Delivery Research · doi:10.3310/hsdr02530 · Cited by 431 · cited 1×
“Therefore, mHealth apps—medical apps in particular—offer the possibility to improve general health care issues and, more specifically, issues related to type 1 (T1DM) and type 2 (T2DM) diabetes mellitus [3,16-18].”
Hou, C., Carter, B., Hewitt, J., Francisa, T., & Mayor, S. (2016) · Diabetes Care · doi:10.2337/dc16-0346 · Cited by 411 · cited 1×
“Hou et al [78] showed in their subgroup analyses that young people with T2DM are more likely to benefit from apps.”
Effectiveness of mHealth interventions for patients with diabetes: An overview of systematic reviews
Kitsiou, S., Paré, G., Jaana, M., & Gerber, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173160 · Cited by 388 · cited 2×
“Moreover, Kitsiou et al [73] investigated the effect of mHealth interventions in general and reported an improvement of –0.3% in HbA 1c levels in people with T1DM.”
Influential
Research works printed but not linked: 8
- Meister, S, 2019, GGW, 19, 7
- Meister, S, 2016, Pfannstiel MA, Da-Cruz P, Mehlich H. editors. Digitale Transformation von Dienstleistungen im Gesundheitswesen I, 185
- Eberle, C, 2020, Stupin J, Schäfer-Graf U, Hummel M. editors, Praxisorientiertes Wissen zu Gestationsdiabetes, Diabetes mellitus Typ 1 und 2, MODY
- Hamidian, K, 2013, Keuper F. editor. Digitalisierung und Innovation: Planung, Entstehung, Entwicklungsperspektiven, 1
- Scherenberg, V, 2013, Strahlendorfditor. Jahrbuch Health Care Marketing, 115
- Gießelmann, K, 2018, Dtsch Arztebl, 115, A538
- 10.1055/s-0035-1549513 · DOI
- Chomutare, T, 2013, Stud Health Technol Inform, 188, 58
Cited by
Digital transformation in healthcare: technology acceptance and its applications
Stoumpos, A. I., Kitsios, F., & Talias, M. A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043407 · Cited by 939
Kerr, D., Ahn, D., Waki, K., Wang, J., Breznen, B., & Klonoff, D. C. (2024) · Journal of Medical Internet Research · doi:10.2196/55757 · Cited by 101
“It has been suggested that digital technology has the potential to support people living with T2DM in their efforts toward achieving their glycemic goals [11,12].”
Stevens, S., Gallagher, S., Andrews, T., Ashall-Payne, L., Humphreys, L., & Leigh, S. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.936752 · Cited by 84
Digital biomarkers: 3PM approach revolutionizing chronic disease management — EPMA 2024 position
Smokovski, I., Steinle, N., Behnke, A., Bhaskar, S. M. M., Grech, G., Richter, K., Niklewski, G., Birkenbihl, C., Parini, P., Andrews, R. J., et al. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00364-6 · Cited by 80
“Mobile apps or surveys administered via digital platforms collect this information and provide insights into the psychological impact of diabetes [46–48] Table 3 Examples of DBs used in CVD care”
MethodTelehealth Technologies in Diabetes Self-management and Education
Sharma, V., Feldman, M., & Sharma, R. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093078 · Cited by 104
Metadata
- Authors
- Eberle, C., Löhnert, M., & Stichling, S.
- Affiliations
- Fulda University of Applied Sciences (DE)
- Corresponding author
- Eberle, Claudia
- Venue
- JMIR mHealth and uHealth
- Publisher
- JMIR Publications Inc.
- Published
- 2021-02-15
- Volume
- 9
- Issue
- 2
- Pages
- e23477
- ISSN
- 2291-5222 (ISSN-L)
- PMC
- PMC7920757
- OpenAlex
- W3109131069
- Cited by
- 160
- References
- 70
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 35 · 2023: 40 · 2022: 20 · 2021: 5
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- JMIR mhealth and uhealth (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Strong
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes mellitus, mobile health apps, type 1 diabetes, type 2 diabetes, gestational diabetes mellitus, HbA1c, glycemic control, self-care, self-efficacy, diabetes management
- MeSH terms
- Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Self Care, Randomized Controlled Trials as Topic, Telemedicine, Mobile Applications, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review. https://app.cochat.ai/papers/10.2196/23477
- The paper
- Eberle, C., Löhnert, M., & Stichling, S. (2021). Effectiveness of Disease-Specific mHealth Apps in Patients With Diabetes Mellitus: Scoping Review. JMIR mHealth and uHealth. https://doi.org/10.2196/23477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
